Head-to-head · free
Doximity, Inc. vs DexCom, Inc.
DOCS vs DXCM — return on capital, cash generation, margins and balance sheet side by side.
DOCS
5 / 10
measures where DOCS leads
DXCM
5 / 10
measures where DXCM leads
A simple count of which company scores better on each measure — not a recommendation to buy or sell.
| Measure | DOCS · FY2026 | DXCM · FY2025 |
|---|---|---|
| Revenue | $644.9M | $4.7B |
| Net income | $196.1M | $836.3M |
| Revenue growth (yearly, multi-year) | 17.0% | 17.5% |
| Free cash flow | $326.5M | $1.1B |
| Free cash flow margin | 50.6% | 23.1% |
| Net cash / (debt) | — | — |
| ROIC | 16.4% | 15.8% |
| Return on equity | 19.3% | 34.5% |
| Gross margin | 89.1% | 60.1% |
| Operating margin | 33.3% | 19.6% |
| Net debt / EBITDA | -0.96x | 0.28x |
Figures are as reported by each company; latest fiscal year shown.
Where Doximity, Inc.'s cash went (FY2026)
- Capital spending
- $0
- Buybacks
- —
- Dividends
- —
- Acquisitions
- —
- Net debt issued / (repaid)
- —
Where DexCom, Inc.'s cash went (FY2025)
- Capital spending
- $363.5M
- Buybacks
- —
- Dividends
- —
- Acquisitions
- —
- Net debt issued / (repaid)
- —
Ask which business is stronger
"Which one reinvests at higher returns?" "Who carries more risk in its filings?" Get answers drawn straight from both companies' filings.
Compare them free